It is unclear whether N-acetylcysteine is useful in preventing contrast-induced nephropathy in patients undergoing coronary angiography. Because of different inclusion and exclusion criteria and different definitions of studied parameters, various studies have reported different outcomes. A systematic search was done using PubMed, Ovid, and the Cochrane library, and studies were pooled after strict inclusion and exclusion criteria. Separate analysis was conducted for all endpoints including only studies that used an N-acetylcysteine (NAC) dose of 600 mg, and another separate analysis was conducted for all endpoints including only studies that used oral route NAC to study how the dose and route of administration of NAC affect the outcomes. The results of the pooled analysis significantly favored the use of NAC to prevent contrast-induced nephropathy in patients undergoing coronary angiography but failed to show any significant benefit in terms of creatinine levels preangiography and postangiography, need for dialysis, and all-cause mortality. The effects of route and dose of NAC did not show any significant difference except in respect to incidence of postcatheterization nephropathy. This study shows that NAC may not have any impact on clinical outcomes after peripheral or coronary artery catheterization and that dose and route do not seem to have any effect on these outcomes.
INTRODUCTION
Contrast-induced nephropathy (CIN) is a well-known and serious complication in coronary diagnostic and interventional procedures, the frequency ranging from 5% in patients with mild renal disease to up to 50% in patients with severely compromised renal disease and diabetes. [1] [2] [3] Different trials have used different definitions for CIN. The most commonly used one includes either a $25% increase in serum creatinine or a rise in serum creatinine of $0.5 mg/dL from baseline value, most commonly occurring 48-72 hours after administration of contrast agent. 4, 5 CIN is associated with a need for dialysis, prolonged hospitalization, and mortality. 2, 4, 6, 7 CIN has also been associated with increase in healthcare costs. 8 Multiple mechanisms have been proposed to explain the pathophysiology of CIN. Contrast agents may cause renal vasoconstriction, leading to prolonged medullary ischemia. 9, 10 Direct renal toxicity caused by production of reactive free radicals has also been reported. 11, 12 Other potential mechanisms that have been reported include immune-mediated apoptosis and interference in glomerular function. 13 Several risk factors have been implicated for the development of CIN. Chronic renal insufficiency, diabetes mellitus, heart failure, old age, and volume and type of contrast agent used have all been reported as risk factors for CIN. 7, [14] [15] [16] [17] [18] Various pharmacological agents have been studied as means to prevent CIN. Use of agents like sodium bicarbonate, diuretics, and statins has yielded inconsistent results. [19] [20] [21] [22] [23] [24] [25] Perhaps, the most extensively studied drug for prevention of CIN is N-acetylcysteine (NAC) and the study results have been conflicting, hence this meta-analysis was done. Currently, there is a lack of consensus in the guidelines on the use of NAC for prevention of CIN. [26] [27] [28] The exact mechanism by which NAC prevents CIN is not known. Antioxidant properties and improvement in renal hemodynamics have been proposed. 29, 30 Both dose and route of administration have been reported to affect the efficacy of NAC in prevention of CIN. 31, 32 Various meta-analysis have found high heterogeneity in the published studies. 33 Despite numerous trials and meta-analyses, it remains unclear whether NAC should be used to prevent contrast-induced nephropathy in patients undergoing coronary angiography. Because of the lack of concurrence between different meta-analysis and heterogeneity among included studies, clinicians often use their own experience to make a choice regarding the usage of NAC. A meta-analysis of randomized controlled trials using strict inclusion criteria to minimize heterogeneity for assessing the efficacy of NAC is presented.
METHODS
Systematic review of medical literature was conducted to identify studies to include in the analysis. The search was done using PubMed, Ovid, and the Cochrane Library. Searches were carried out using the following terms individually to ensure that the largest number of potentially relevant studies would be retrieved: "catheterization" and "N-acetylcysteine." Combinations of these terms were then used in searches to assist in study selection.
The articles were initially screened by title and abstract. Studies were deemed appropriate for further analysis if the following criteria were met: the article was in English; was a randomized controlled trial; compared 2 groups of patients, one with patients Full text of the articles found appropriate for further evaluation was obtained. Studies with redundant data, lack of relevant data, or unusable data were excluded and the remainder were included in the pooled analysis.
Evaluation of all articles was done by 2 separate authors who scored each article based on the inclusion criteria. Differences in scoring between authors were then evaluated by the third author. Data were extracted from studies selected to be included by 2 individual authors, and results were compared by the third author to ensure accuracy of data extraction. Study selection methodology is outlined in Figure 1 .
A pooled analysis was used to evaluate the effect of NAC on each endpoint, individually. A mean difference and 95% confidence interval (CI) were calculated for continuous variables, whereas a common odds ratio and 95% CI were calculated for odds ratio variables. The Mantel-Haenszel fixed effects model was used for the analysis of endpoints that demonstrated homogeneity, whereas the random effects model was used for the analysis of endpoints that demonstrated heterogeneity. A 2-sided alpha error of less than 0.05 was considered to be statistically significant. Results of heterogeneity analysis for each endpoint are included in its respective forest plot.
A separate analysis was conducted for all endpoints including only studies that used an NAC dose of 600 mg, and another separate analysis was conducted for all endpoints including only studies that used oral route NAC. These were conducted to study the effect of route and dose of NAC may have on its efficacy in the setting of preventing CIN. If the overall effect of NAC on the studied endpoint was the same between the total analysis and the subanalysis, the subanalysis variable was considered to have no impact. If the overall effect of NAC on the studied endpoint was different between the total analysis and the subanalysis, then the variable was considered to have an impact. Studies excluded in the subanalyses are still shown on the forest plots but do not have a mean difference or odds ratio and CI plotted.
RESULTS
Searching PubMed, Ovid, and Cochrane Library, 11,598 articles were found when "N-acetylcysteine" was used as the search term and 185,647 when "catheterization." Secondary search terms for which results were cross referenced included "contrast induced nephropathy," "angiography," and "coronary intervention." When search terms were used together, 132 articles were found. After identifying redundant results, 120 articles were found to be appropriate for full text evaluation. Ultimately, 27 studies were included in the analysis. A total of 4 endpoints were extracted from 27 studieschange in creatinine, incidence of CIN, incidence of dialysis, and incidence of all-cause mortality.
The characteristics of each individual trial included are shown in Table 1 . There were no significant differences in patient demographics between the 2 groups included.
Sixteen studies were pooled for the analysis of change in creatinine 48 hours after angiography. Heterogeneity analysis resulted in a x 2 test (307.01, df 5 15, P , 0.00001) that demonstrated heterogeneity between studies. The pooled mean difference was found to be 20.10 with a 95% CI of 20.22 to 0.03 using the random effects model. This result insignificantly favored NAC (Figure 2 ). Subgroup analysis did not result in a difference in outcome when dose ( Figure 3 ) and route were accounted for by eliminating studies with doses other than 600 mg and an intravenous route (Figure 4) .
Twenty-three studies were pooled for the analysis of CIN after angiography. Heterogeneity analysis resulted in a x 2 (25.32, df 5 16, P 50.06) that demonstrated homogeneity between studies. The pooled mean difference was found to be 0.89 with a 95% CI of 0.74-1.08 using the fixed effects model. This result insignificantly favored NAC ( Figure 5 ). Subgroup analysis did result in a difference in outcome when dose ( Figure 6 ) was accounted for but not when route was accounted for (Figure 7) .
Seven studies were pooled for the analysis of need for dialysis after angiography. Heterogeneity analysis resulted in a x 2 (2.69, df 5 5, P 5 0.75) that demonstrated homogeneity between studies. The pooled mean difference was found to be 1.66 with a 95% CI of 0.67-4.12 using the fixed effects model. This result insignificantly favored placebo (Figure 8 ). Subgroup analysis did not result in a difference in outcome when dose ( Figure 9 ) and route were accounted for ( Figure 10) .
Seven studies were pooled for the analysis of allcause mortality. Heterogeneity analysis resulted in a x 2 (3.54, df 5 6, P 5 0.74) that demonstrated homogeneity between studies. The pooled mean difference was found to be 0.85 with a 95% CI of 0.56-1.29 using the fixed effects model. This result insignificantly favored NAC (Figure 11 ). Subgroup analysis did not result in a difference in outcome when dose ( Figure 12 ) and route were accounted for ( Figure 13 ).
Funnel plot analysis was conducted to assess for bias between studies. Funnel plots for change in creatinine, incidence of CIN, need for dialysis, and all-cause mortality are show in Figures 14-17 .
DISCUSSION
This meta-analysis shows that NAC has an insignificant impact on the change between precatheterization and 48-hour postcatheterization creatinine levels, an insignificant impact on the need for dialysis postcatheterization, and an insignificant impact on all-cause mortality postcatheterization when compared with placebo. NAC was found, however, to be associated with a significant reduction in CIN when compared with placebo. Subanalyses demonstrate that dose and route of NAC do not impact any of these outcomes except for CIN. Removal of studies using intravenous, rather than oral, NAC resulted in an insignificant effect on CIN.
Compared with previous meta-analyses on the topic, this analysis uses a more stringent inclusion criteria, eliminating heterogeneity in almost all endpoints studied. Recent trials, not included in previous analyses, are also included in this analysis. This analysis pools data across 4 endpoints relevant to CIN and also includes subanalysis in respect to dose and route. Loomba et al NAC has also been studied in direct comparison or in addition to other potential agents to prevent CIN. It has been reported to be superior to fenoldopam and ascorbic acid in preventing CIN. 34, 35 NAC was found to be inferior to sodium bicarbonate in preventing CIN in 1 trial, although this association was statistically insignificant. 36 The combination of NAC with sodium bicarbonate has been reported to be associated with conflicting results in prevention of CIN. [37] [38] [39] Recently, intravenous glutathione has also been studied for prevention of CIN and was reported to be more effective in preventing oxidative stress when compared with NAC. 40 Cystatin C has been reported to be more useful than serum creatinine in detecting early renal dysfunction. 41, 42 In one study, cystatin C levels were found to be unchanged after receiving NAC in patients with normal renal function, although a contrast agent was not administered in this study. 43 However, another study of patients with normal renal function undergoing coronary angiography reported that NAC independently protected against the development of cystatin C-based CIN and trended toward protection against serum creatinine-based CIN. 44 This study is limited by issues inherent in meta-analyses. Heterogeneity was present only in 1 endpoint: change in creatinine precatheterization and postcatheterization. This heterogeneity is the result of variation in the effect size of included studies rather than differences in individual study methodology. A random effects model was used in the analysis of this endpoint to adjust for the heterogeneity. Analysis of publication bias for the endpoint of CIN demonstrates no apparent publication bias, whereas there seems to be a lack of smaller studies deviating from the mean effect in both the negative and the positive directions for change in creating precatheterization and postcatheterization. Analysis of publication bias for the other endpoints could not be formally done because of the number of pooled studies being less than 10 for these endpoints.
CONCLUSIONS
NAC does seem to lower the incidence of CIN slightly after catheterization, although it does not significantly impact change in creatinine levels precatheterization and postcatheterization, need for dialysis, or all-cause mortality. The decrease in CIN may be negligible, despite being significant, because there was a very small difference in odds ratio and no significant difference on clinical endpoints, such as need for dialysis or mortality.
